<DOC>
	<DOCNO>NCT02320019</DOCNO>
	<brief_summary>Research Hypothesis : There great proportion VAS responder define achieve ≥ 50 % reduction baseline VAS low back pain week 12 follow intradiscal injection YH14618 compare placebo . Patients diagnose one two symptomatic lumbar degenerative disc disease define Pfirrmann grade 2 4 use MRI . Patients suffer persistent low back pain least 3 month conservative therapy must low back pain measure VAS≥4 cm modify Oswestry disability index ( mODI ) ≥30 % baseline .</brief_summary>
	<brief_title>Clinical Trial YH14618 Patients With Degenerative Disc Disease</brief_title>
	<detailed_description />
	<mesh_term>Intervertebral Disc Degeneration</mesh_term>
	<criteria>Patients diagnose one two symptomatic early lumbar ( L1/L2 ~ L5/S1 ) degenerative disc disease define Pfirrmann grade 2 4 use MRI perform within 4 week prior randomization . Patients suffer persistent low back pain least 3month conservative therapy . Patients low back pain measure VAS≥4cm mODI≥30 % screen randomization visit ( Day 0 ) . Clinically significant spine compression fracture , spinal stenosis , spinal instability . Clinically significant sacroiliac joint dysfunction , facet joint pain , suspect . Modic change type III assess Xray MRI History spine surgery Neurologic disorder . Any systemic disease influence spine rheumatoid arthritis , ankylose spondylitis , autoimmune disease . Participation clinical trial intradiscal injection ( eg , Phase 1/2a YH14618201 trial , Cell therapy , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>